Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15838249rdf:typepubmed:Citationlld:pubmed
pubmed-article:15838249lifeskim:mentionsumls-concept:C0029408lld:lifeskim
pubmed-article:15838249lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:15838249lifeskim:mentionsumls-concept:C0013725lld:lifeskim
pubmed-article:15838249lifeskim:mentionsumls-concept:C0442844lld:lifeskim
pubmed-article:15838249pubmed:issue3lld:pubmed
pubmed-article:15838249pubmed:dateCreated2005-4-19lld:pubmed
pubmed-article:15838249pubmed:abstractTextEicosanoids are produced by chondrocytes, synoviocytes, and subchondral osteoblasts within the osteoarthritic joint and are involved in normal joint physiology as well as in the pathogenesis of joint disorders such as osteoarthritis. Calcium-containing crystals are found in most osteoarthritic joints and have been implicated in osteoarthritis. Recent advances in the understanding of the potential role of eicosanoids in the pathogenesis of osteoarthritis and in potential therapeutic targeting of eicosanoid pathways are reviewed.lld:pubmed
pubmed-article:15838249pubmed:languageenglld:pubmed
pubmed-article:15838249pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15838249pubmed:citationSubsetIMlld:pubmed
pubmed-article:15838249pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15838249pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15838249pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15838249pubmed:statusMEDLINElld:pubmed
pubmed-article:15838249pubmed:monthMaylld:pubmed
pubmed-article:15838249pubmed:issn1040-8711lld:pubmed
pubmed-article:15838249pubmed:authorpubmed-author:McCarthyGeral...lld:pubmed
pubmed-article:15838249pubmed:authorpubmed-author:MolloyEamonn...lld:pubmed
pubmed-article:15838249pubmed:issnTypePrintlld:pubmed
pubmed-article:15838249pubmed:volume17lld:pubmed
pubmed-article:15838249pubmed:ownerNLMlld:pubmed
pubmed-article:15838249pubmed:authorsCompleteYlld:pubmed
pubmed-article:15838249pubmed:pagination346-50lld:pubmed
pubmed-article:15838249pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:15838249pubmed:meshHeadingpubmed-meshheading:15838249...lld:pubmed
pubmed-article:15838249pubmed:meshHeadingpubmed-meshheading:15838249...lld:pubmed
pubmed-article:15838249pubmed:meshHeadingpubmed-meshheading:15838249...lld:pubmed
pubmed-article:15838249pubmed:meshHeadingpubmed-meshheading:15838249...lld:pubmed
pubmed-article:15838249pubmed:meshHeadingpubmed-meshheading:15838249...lld:pubmed
pubmed-article:15838249pubmed:meshHeadingpubmed-meshheading:15838249...lld:pubmed
pubmed-article:15838249pubmed:year2005lld:pubmed
pubmed-article:15838249pubmed:articleTitleEicosanoids, osteoarthritis, and crystal deposition diseases.lld:pubmed
pubmed-article:15838249pubmed:affiliationDepartment of Clinical Pharmacology, Royal College of Surgeons of Ireland, Dublin, Ireland. emolloy2@rcsi.ielld:pubmed
pubmed-article:15838249pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15838249pubmed:publicationTypeReviewlld:pubmed